Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 31;22(11):5899.
doi: 10.3390/ijms22115899.

CAR-NK Cells in the Treatment of Solid Tumors

Ewa Wrona  1   2 , Maciej Borowiec  1 , Piotr Potemski  2
Affiliations
Review

CAR-NK Cells in the Treatment of Solid Tumors

Ewa Wrona et al. Int J Mol Sci. .

Abstract

CAR-T (chimeric antigen receptor T) cells have emerged as a milestone in the treatment of patients with refractory B-cell neoplasms. However, despite having unprecedented efficacy against hematological malignancies, the treatment is far from flawless. Its greatest drawbacks arise from a challenging and expensive production process, strict patient eligibility criteria and serious toxicity profile. One possible solution, supported by robust research, is the replacement of T lymphocytes with NK cells for CAR expression. NK cells seem to be an attractive vehicle for CAR expression as they can be derived from multiple sources and safely infused regardless of donor-patient matching, which greatly reduces the cost of the treatment. CAR-NK cells are known to be effective against hematological malignancies, and a growing number of preclinical findings indicate that they have activity against non-hematological neoplasms. Here, we present a thorough overview of the current state of knowledge regarding the use of CAR-NK cells in treating various solid tumors.

Keywords: chimeric antigen receptor (CAR); natural killer (NK) cell; review; solid tumors.

PubMed Disclaimer

Conflict of interest statement

P.P.—research funding: Roche, AstraZeneca, GSK. Travel grants: Roche, Novartis. Lecture fees: Novartis, AstraZeneca, Ipsen. Advisory fees: Servier. E.W. and M.B.—no relevant conflicts of interest.

References

    1. Rohaan M.W., Wilgenhof S., Haanen J.B.A.G. Adoptive cellular therapies: The current landscape. Virchows Arch. 2019;474:449–461. doi: 10.1007/s00428-018-2484-0. - DOI - PMC - PubMed
    1. Rafiq S., Hackett C.S., Brentjens R.J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 2020;17:147–167. doi: 10.1038/s41571-019-0297-y. - DOI - PMC - PubMed
    1. Liu E., Marin D., Banerjee P., Macapinlac H.A., Thompson P., Basar R., Kerbauy L.N., Overman B., Thall P., Kaplan M., et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N. Engl. J. Med. 2020;382:545–553. doi: 10.1056/NEJMoa1910607. - DOI - PMC - PubMed
    1. Basar R., Daher M., Rezvani K. Next-generation cell therapies: The emerging role of CAR-NK cells. Blood Adv. 2020 doi: 10.1182/bloodadvances.2020002547. - DOI - PMC - PubMed
    1. Schönfeld K., Sahm C., Zhang C., Naundorf S., Brendel C., Odendahl M., Nowakowska P., Bönig H., Köhl U., Kloess S., et al. Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor. Mol. Ther. 2015 doi: 10.1038/mt.2014.219. - DOI - PMC - PubMed

MeSH terms

Substances